James R. Empfield - Net Worth and Insider Trading

James R. Empfield Net Worth

The estimated net worth of James R. Empfield is at least $380,900 dollars as of 2024-06-01. James R. Empfield is the EVP, Drug Discovery of Xenon Pharmaceuticals Inc and owns about 10,000 shares of Xenon Pharmaceuticals Inc (XENE) stock worth over $380,900. Details can be seen in James R. Empfield's Latest Holdings Summary section.

Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the assumption that James R. Empfield has not made any transactions after 2022-08-12 and currently still holds the listed stock(s).

Transaction Summary of James R. Empfield

To

James R. Empfield Insider Ownership Reports

Based on ownership reports from SEC filings, as the reporting owner, James R. Empfield owns 1 companies in total, including Xenon Pharmaceuticals Inc (XENE) .

Click here to see the complete history of James R. Empfield’s form 4 insider trades.

Insider Ownership Summary of James R. Empfield

Ticker Comapny Transaction Date Type of Owner
XENE Xenon Pharmaceuticals Inc 2022-08-12 SVP & Drug Discovery

James R. Empfield Latest Holdings Summary

James R. Empfield currently owns a total of 1 stock. James R. Empfield owns 10,000 shares of Xenon Pharmaceuticals Inc (XENE) as of August 12, 2022, with a value of $380,900.

Latest Holdings of James R. Empfield

Ticker Comapny Latest Transaction Date Shares Owned Current Price ($) Current Value ($)
XENE Xenon Pharmaceuticals Inc 2022-08-12 10,000 38.09 380,900

Holding Weightings of James R. Empfield


James R. Empfield Form 4 Trading Tracker

According to the SEC Form 4 filings, James R. Empfield has made a total of 2 transactions in Xenon Pharmaceuticals Inc (XENE) over the past 5 years, including 0 buys and 2 sells. The most-recent trade in Xenon Pharmaceuticals Inc is the sale of 57,743 shares on August 12, 2022, which brought James R. Empfield around $2 Million.

Insider Trading History of James R. Empfield

No transactions are available. GuruFocus only tracks and displays the purchase and sale of non-derivative security in open market or private transactions from SEC filings with the transaction code of P or S.
Total 0
  • 1
Only the transactions in Open Market or Private Sale at the market prices are included. Other transactions such as conversion of derivative security or exercise of options are not included. Insiders are limited to only officers and/or directors of the company.

James R. Empfield Trading Performance

GuruFocus tracks the stock performance after each of James R. Empfield's buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by James R. Empfield is -10.2%. GuruFocus also compares James R. Empfield's trading performance to market benchmark return within the same time period. The performance of stocks bought by James R. Empfield within 3 months outperforms 0 times out of 1 transactions in total compared to the return of S&P 500 within the same period.

You can select different timeframes to see how James R. Empfield's insider trading performs compared to the benchmark.

Please note GuruFocus will not track the insiders’ transaction performance if he/she does not have buying transactions.

Performance of James R. Empfield

Average Return

LIMIT
Average return per transaction

Outperforming Transactions

LIMIT
1 out of 1 outperforming transactions.
Each transaction is measured over a period and compared to .
1 Month 3 Months 6 Months 1 Year 2 Years 3 Years
Return(%) 28.57 LIMIT LIMIT LIMIT LIMIT LIMIT
Relative Return to S&P 500(%) 27.12 LIMIT LIMIT LIMIT LIMIT LIMIT

James R. Empfield Ownership Network

Ownership Network List of James R. Empfield

No Data

Ownership Network Relation of James R. Empfield

Insider Network Chart

James R. Empfield Owned Company Details

What does Xenon Pharmaceuticals Inc do?

Who are the key executives at Xenon Pharmaceuticals Inc?

James R. Empfield is the SVP & Drug Discovery of Xenon Pharmaceuticals Inc. Other key executives at Xenon Pharmaceuticals Inc include SVP Bus. & Corp. Development Sherrington Robin , director & PRESIDENT & CEO Ian Mortimer , and Chief Medical Officer Christopher John Kenney .

Xenon Pharmaceuticals Inc (XENE) Insider Trades Summary

Over the past 18 months, James R. Empfield made no insider transaction in Xenon Pharmaceuticals Inc (XENE). Other recent insider transactions involving Xenon Pharmaceuticals Inc (XENE) include a net sale of 150,477 shares made by Simon N. Pimstone , a net sale of 26,576 shares made by Gary Patou , and a net sale of 31,655 shares made by Ian Mortimer .

In summary, during the past 3 months, insiders sold 22,229 shares of Xenon Pharmaceuticals Inc (XENE) in total and bought 0 shares, with a net sale of 22,229 shares. During the past 18 months, 256,637 shares of Xenon Pharmaceuticals Inc (XENE) were sold and 0 shares were bought by its insiders, resulting in a net sale of 256,637 shares.

Xenon Pharmaceuticals Inc (XENE)'s detailed insider trading history can be found in Insider Trading Tracker table.

To

Xenon Pharmaceuticals Inc Insider Transactions

No Available Data

James R. Empfield Mailing Address

Above is the net worth, insider trading, and ownership report for James R. Empfield. You might contact James R. Empfield via mailing address: 200 - 3650 Gilmore Way, Burnaby A1 Vg5 48w.

Discussions on James R. Empfield

No discussions yet.